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==========

The study planned to determine the MTD and preliminary pharmacokinetic (PK) characteristics of X‐82, administered as a single agent in a continuous daily dosing schedule, in patients with advanced solid tumors. The study began with a capsule formulation of X‐82. To improve the absorption and exposure of X‐82, a tablet formulation was available with protocol Amendment 3, and patients receiving capsules had the option to switch to the tablet formulation based on availability.

###### Treatment‐related adverse events (incidence ≥5%; *n* = 52)

![](onco12753-tbl-0001){#nlm-graphic-1}

Data are presented as *n* (%).

Abbreviation: ---, no occurrence.

Patients on cohorts 1--6 received 20--400 mg once‐daily capsule dosing and patients on cohorts 7 and 8 received 140--200 mg twice‐daily capsule dosing. Patients on cohorts 9--17 received 50--800 mg once‐daily tablet dosing. Patients were enrolled sequentially into these cohorts. No dose‐limiting toxicities were observed in the dose levels explored. However, enrollment was stopped prior to determination of the MTD because of the apparent saturation of absorption at 400--800 mg. The recommended dose of X‐82 monotherapy in patients with advanced cancer is 400 mg once daily.

To achieve the PK/pharmacodynamic (PD) model reported by Mendel et al., X‐82 was designed to have a short *t*~1/2~ and no accumulation in humans. The PK results underscore that our X‐82 study design was successful without the need for further dose escalation beyond 400 mg once daily. In summary, X‐82 was well tolerated by most patients, with the most common treatment‐related grade 3 adverse event (AE) being proteinuria (4%). There were no grade ≥ 4 AEs or deaths thought to be related to X‐82. This safety profile is consistent with the mechanism of action. Further improvements in the treatment of advanced cancers with X‐82 will likely await identification of and successful combination with other agents.

![Best response as change from baseline for the sum of target lesions (*n* = 49). Two patients stopped study treatment during Cycle 1 because of clinical progression and were not reassessed for response. †Hurthle cell carcinoma. ††Pancreatic cancer.](onco12753-fig-0001){#onco12753-fig-0001}

Trial Information {#onco12753-sec-0008}
=================

DiseaseAdvanced cancer/solid tumor onlyStage of Disease/TreatmentMetastatic/advancedPrior TherapyMore than two prior regimensType of Study -- 1Phase IType of Study -- 23 + 3Primary EndpointMaximum tolerated doseSecondary EndpointPharmacokineticsSecondary EndpointSafetySecondary EndpointEfficacySecondary EndpointProportion of patients with an overall tumor response (complete response + partial response)Secondary EndpointDuration of responseSecondary EndpointProportion of patients with stable diseaseAdditional Details of Endpoints or Study Design **Additional Notes on Prior Therapy:** Dose escalation phase: There was no limit on the amount of prior chemotherapy; dose expansion phase: ≤3 prior cytotoxic treatment regimens, and at least 1 regimen must have included a platinum‐containing agent. **Dose Escalation Schema:** Once‐daily dosing regimen used an accelerated titration scheme that evaluated at least one patient per 28‐day cycle before escalation to the next dose level. This accelerated titration scheme was to be followed by a 3 + 3 dose escalation (see Protocol Amendment 2). However, based on preliminary PK data from patients in this study, an apparent saturation in absorption of the drug capsule was observed, with a plateau in drug exposure at q.d. doses ≥160 mg. As a result, b.i.d. dosing was employed to further increase exposure and evaluate toxicity (Protocol Amendment 2). A new X‐82 tablet formulation was introduced at a starting dose of 50 mg once or twice daily depending on data evaluation from the prior cohort using a 3 + 3 design. **Investigator**\'**s Analysis**Active and should be pursued further

Drug Information {#onco12753-sec-1008}
================

Drug 1 Generic/Working NameX‐82Trade NameVorolanibCompany NameEquinox Sciences, LLCDrug TypeSmall moleculeDrug ClassAngiogenesis ‐ antivascularDoseX‐82 Capsule formulation: 20 mg and 100 mg (for patients enrolled prior to amendment 3); Tablet formulation: 50 mg and 100 mg (for patients enrolled after amendment 3)Routep.o.

Dose Escalation Table {#onco12753-sec-1009}
=====================
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Patient Characteristics {#onco12753-sec-1010}
=======================

**Number of Patients, Male**38 (73%)**Number of Patients, Female**14 (27%)**Stage**Advanced**Age**Median (range): 64 (40--80)**Number of Prior Systemic Therapies**Median (range): not collected**Performance Status: ECOG**0 --- 34 (65%)1 --- 18 (35%)2 --- 03 --- 0Unknown --- 0**Other**Race: white, 49 (94%); black, 1 (2%); American Indian/Alaskan Native, 2 (4%)**Cancer Types or Histologic Subtypes**Breast, 1 (2%)Lung, non‐small cell, 1 (2%)Lung, small cell, 2 (4%)Ovarian ‐ platinum sensitive, 3 (6%)Ovarian ‐ primary platinum resistant, 2 (4%)Ovarian ‐ secondary platinum resistant, 2 (4%)Ovarian ‐ platinum refractory, 3 (6%)Pancreatic, 1 (2%)Endometrial, 6 (12%)Colorectal, 8 (15%)Sarcoma, 2 (4%)Renal, 3 (6%)Gastrointestinal stroma, 1 (2%)Other\*, 17 (33%)\*Carcinoid (3, 6%); cervical (2, 4%); clear cell ovary; gastric, Hurthle cell carcinoma of right thyroid; liver; melanoma; neuroendocrine carcinoid tumor; parotid gland; squamous cell carcinoma of the vulva; thyroid; unknown primary; uterine; and vagina (1 patient each, 2%). 

Primary Assessment Method {#onco12753-sec-1011}
=========================

TitleAssessmentNumber of Patients Enrolled52Number of Patients Evaluable for Toxicity52Number of Patients Evaluated for Efficacy49Evaluation MethodRECIST 1.1Response Assessment CR*n* = 1 (2%)Response Assessment PR*n* = 1 (2%)Response Assessment SD*n* = 25 (51%)Response Assessment PD*n* = 20 (41%)Response Assessment OTHER*n* = 2 (4%)(Median) Duration Assessments PFS2 months, CI: 95%(Median) Duration Assessments TTP2 months, CI: 95%(Median) Duration Assessments Response Duration5 months(Median) Duration Assessments Duration of Treatment58 daysOutcome NotesOther = missing, 2 (4%). Note that 11 patients (22%) had stable disease and were on study for at least six cycles.

Adverse Events {#onco12753-sec-1012}
==============

imageJohn Wiley & Sons, Ltd.[^3]

Serious Adverse Events {#onco12753-sec-1013}
======================

imageJohn Wiley & Sons, Ltd.[^4]

Assessment, Analysis, and Discussion {#onco12753-sec-1028}
====================================

CompletionStudy terminated before completionTerminated ReasonDid not fully accrue**Investigator**\'**s Assessment**Active and should be pursued further

 {#onco12753-sec-1014}

Vascular endothelial growth factor receptor (VEGFR) and platelet‐derived growth factor receptor (PDGFR) are cell surface tyrosine kinase receptors that represent targets for anticancer therapy in solid tumors. The combined effect on VEGFR and PDGFR with similar potency is thought to contribute to the increased efficacy of sunitinib (SU11248) over other tyrosine kinase inhibitors (TKIs) such as sorafenib, in patients with renal cell carcinoma, that primarily target VEGFR \[[1](#onco12753-bib-0001){ref-type="ref"}\]. Vorolanib (X‐82) was developed on the same chemical scaffold as sunitinib, targets all isoforms of VEGFR and PDGFR, and was designed to improve the safety profile while maintaining the efficacy of sunitinib.

Clinical studies showed that sunitinib has a long *t*~1/2~ (\>40 hours) as well as large distribution and accumulation in various tissues \[[2](#onco12753-bib-0002){ref-type="ref"}\]. This observation required sunitinib dosing holidays as reflected in the U.S. Food and Drug Administration‐approved dose of 50 mg once daily with 4 weeks on and 2 weeks off (4/2) treatment in metastatic renal cell carcinoma \[[3](#onco12753-bib-0003){ref-type="ref"}\]. However, murine pharmacokinetic (PK)/pharmacodynamic (PD) studies of sunitinib suggested that constant inhibition of VEGFR2 and PDGFRβ phosphorylation was not required for efficacy; at highly efficacious doses, inhibition was sustained for 12 hours of a 24‐hour dosing interval \[[4](#onco12753-bib-0004){ref-type="ref"}\]. With a *t*~1/2~ of about 2 hours in mice, sunitinib displayed intermittent inhibition with daily dosing; however, as the *t*~1/2~ in humans is much longer, daily dosing results in constant inhibition. X‐82 was designed to have a short *t*~1/2~ in humans to meet the PK/PD requirement of intermittent inhibition with daily dosing. X‐82 was also designed to have a smaller volume of distribution in tissues because its therapeutic targets, VEGFR and PDGFR, are in blood vessels. It was hypothesized that if X‐82 had a short *t*~1/2~ and did not accumulate in tissues, it would meet the requirement of intermittent inhibition and minimize the potential for toxicity, while maintaining antitumor activity similar to sunitinib.

The objective of this study was to determine the maximum tolerated dose (MTD) and preliminary PK of single‐agent X‐82 in patients with advanced solid tumors. The expectation was that an improved safety profile would allow daily dosing of X‐82 and permit combination modalities currently precluded by safety concerns with sunitinib. Enrollment was stopped prior to determination of the MTD because of the apparent saturation of absorption at 400--800 mg. We believe that X‐82 proved to be less toxic, as proteinuria (two patients, 4%) was the most common treatment‐related adverse event reported. Additionally, we considered the intermittent suppression to be clinically effective. In a small phase I/II trial in patients with renal cell carcinoma (about half TKI naïve, half received prior TKI), its efficacy was comparable to other TKIs, but much better tolerated, consistent with the PK/PD model. Finally, the drug sponsor, Xcovery, LLC, has three clinical trials ongoing to investigate the X‐82 combination with anti‐programmed cell death protein 1 therapies (NCT03511222, NCT03583086, NCT03602547).

Figures and Tables {#onco12753-sec-3013}
==================

![Cycle 1 Day 22 arithmetic mean plasma concentration time curves with tablet formulation of X‐82.](onco12753-fig-0002){#onco12753-fig-0002}

###### Cycle 1 Day 22 mean PK parameters in patients administered X‐82 tablets

![](onco12753-tbl-0010){#nlm-graphic-17}

Abbreviations: AUC, area under the plasma‐concentration time curve from time zero to 22 days; C~max~, peak drug concentration; fast, fasting; fed, with meal; PK, pharmacokinetic; T~max~, time to maximum observed concentration; *t*~1/2~, terminal half‐life.

###### Cancer antigen 125 response (*n* = 14)

![](onco12753-tbl-0011){#nlm-graphic-19}

One patient achieved stable disease and remained on treatment for at least six cycles.

![Time to progression (TTP). Sample size, 49 patients; median progression‐free survival (95% confidence interval \[CI\]): 2.00 (1.8--3.7); median TTP (95% CI): 2.00 (1.8--3.7).](onco12753-fig-0003){#onco12753-fig-0003}

![Progression‐free survival. Sample size, 49 patients; median progression‐free survival (95% confidence interval): 2.00 (1.8--3.7).](onco12753-fig-0004){#onco12753-fig-0004}
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[Click here to access other published clinical trials](http://theoncologist.alphamedpress.org/cgi/collection/clinical-trial-results).
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[^1]: Each X‐82 dose was a cohort. For the 150 mg q.d., there were two cohorts: Cohort 11, 150 mg q.d., five patients; and Cohort 12, 150 mg q.d., three patients.

[^2]: Abbreviations: b.i.d., twice daily; q.d., once daily.

[^3]: Abbreviation: NC/NA, no change from baseline/no adverse event.

[^4]: Note that two patients experienced a serious adverse event of grade 3 anemia that was unrelated to X‐82. In addition, two patients experienced a serious adverse event of grade 3 dyspnea that was unrelated to X‐82.
